Atrium Therapeutics Opens Enrollment in PRKAG2 Syndrome Trial Funded by BMS Collaboration
Atrium Therapeutics opens enrollment in PRKAG2 Syndrome Trial for ATR 1072, an siRNA candidate targeting rare cardiomyopathy.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 EGFR Exon 20 Trial
Zipalertinib plus chemotherapy met its primary progression-free survival endpoint in the Phase 3 REZILIENT3 trial for EGFR exon 20...
FDA Clears Denifanstat Phase 3 Trial for Moderate to Severe Acne
FDA clears denifanstat Phase 3 trial for moderate to severe acne. The FASN inhibitor showed 61.3% lesion reduction in...
Atea’s Bemnifosbuvir/Ruzasvir Meets Phase 3 Endpoints in Hepatitis C Trial
Atea's bemnifosbuvir/ruzasvir met Phase 3 endpoints in the C-BEYOND hepatitis C trial, advancing toward NDA submission and regulatory review.
ArkBio’s AK0406 Influenza Drug Advances to China Clinical Trials
ArkBio's AK0406 influenza drug advances to China clinical trials after completing Phase 1 dosing in Australia, targeting both flu...
Talphera’s nafamostat gains KDIGO endorsement as NEPHRO CRRT trial nears completion
Talphera's NEPHRO CRRT trial nears completion at 75% enrollment while nafamostat gains KDIGO guideline endorsement for acute kidney injury...
Definium’s DT120 Meets Primary Endpoint in Phase 3 Anxiety Trial
Definium's DT120 meets primary endpoint in Phase 3 anxiety trial with 5.4-point HAM-A separation from placebo at week 12.
TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year
TherapeuticsMD's license revenue drops 8.7% year-over-year in Q2 2026, with net income falling 70% as the company relies solely...
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms
AbCellera's ABCL635 Phase 2 trial met primary endpoints for menopause vasomotor symptoms, showing statistically significant reductions in frequency and...
Theriva Biologics reports $11.3M cash, 3-4 quarters runway for VCN-01 trial
Theriva Biologics reports $11.3M cash with 3-4 quarters runway to advance its VCN-01 trial in metastatic pancreatic cancer.